Posted by Michael Wonder on 27 Jul 2017
Priority review vouchers for tropical disease drugs simply aren’t working
25 July 2017 - A controversial program created by Congress to spur development of new drugs for neglected tropical diseases has failed to achieve its goals, according to a new analysis.
Known as priority review vouchers, these are awarded to drug makers that win regulatory approval of a tropical disease treatment and can later be redeemed when the company seeks approval for yet another medicine for treating any illness. Moreover, the FDA must review the other drug in six months, instead of the standard 10 months.
